Home Featured Page 271

Featured

Latest

The Potential of Buprenorphine, the Risks of Ketamine, and How Psychedelics Could Prevent Nuclear War

Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects on Lykos’ Strategy; Polish Psilocybin Study Scores $4M in Funding

Regulation, Decriminalization, and Religious Freedom: Prop 122’s Challenges and Opportunities

Inside the FDA’s Psychedelics Journey: Javier Muniz, MD on Breakthroughs, Challenges, and the Future of the Field

How Family Healing Shapes Veteran Recovery

PT230 – Penny White of NeonMind Biosciences

DMT for Depression: Paving the Way for New Medicine

Changa vs. DMT: What You Need to Know

Is the DMT Experience a Hallucination?

DMT Art: A Look Behind Visionary Creations

How to Get DMT: Obtaining the Spirit Molecule

Dr. Carl Hart: Demystifying Drugs

Joe Biden’s Evolution on Drug Policy

1...270271272...277 Page 271 of 277

The Potential of Buprenorphine, the Risks of Ketamine, and How Psychedelics...

Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects...

Regulation, Decriminalization, and Religious Freedom: Prop 122’s Challenges and Opportunities

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Potential of Buprenorphine, the Risks of Ketamine, and How Psychedelics Could Prevent Nuclear War

Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects on Lykos’ Strategy; Polish Psilocybin Study Scores $4M in Funding

Regulation, Decriminalization, and Religious Freedom: Prop 122’s Challenges and Opportunities

Inside the FDA’s Psychedelics Journey: Javier Muniz, MD on Breakthroughs, Challenges, and the Future of the Field

How Family Healing Shapes Veteran Recovery

PT230 – Penny White of NeonMind Biosciences

DMT for Depression: Paving the Way for New Medicine

Changa vs. DMT: What You Need to Know

Is the DMT Experience a Hallucination?

Why Does DMT Pervade Nature?

DMT Art: A Look Behind Visionary Creations

Mapping the DMT Experience

How to Get DMT: Obtaining the Spirit Molecule

Dr. Carl Hart: Demystifying Drugs

Joe Biden’s Evolution on Drug Policy

EDITOR PICKS

The Potential of Buprenorphine, the Risks of Ketamine, and How Psychedelics...

Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects...

Regulation, Decriminalization, and Religious Freedom: Prop 122’s Challenges and Opportunities

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY